[go: up one dir, main page]

SG11201708680PA - Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr) - Google Patents

Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr)

Info

Publication number
SG11201708680PA
SG11201708680PA SG11201708680PA SG11201708680PA SG11201708680PA SG 11201708680P A SG11201708680P A SG 11201708680PA SG 11201708680P A SG11201708680P A SG 11201708680PA SG 11201708680P A SG11201708680P A SG 11201708680PA SG 11201708680P A SG11201708680P A SG 11201708680PA
Authority
SG
Singapore
Prior art keywords
tcr
activated
specific
cells expressing
cell receptor
Prior art date
Application number
SG11201708680PA
Inventor
Antonio Bertoletti
Sarene Koh
Original Assignee
Lion Tcr Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Tcr Pte Ltd filed Critical Lion Tcr Pte Ltd
Publication of SG11201708680PA publication Critical patent/SG11201708680PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201708680PA 2016-03-31 2016-03-31 Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr) SG11201708680PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG2016/050164 WO2017171631A1 (en) 2016-03-31 2016-03-31 Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr)

Publications (1)

Publication Number Publication Date
SG11201708680PA true SG11201708680PA (en) 2017-11-29

Family

ID=59965039

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201708680PA SG11201708680PA (en) 2016-03-31 2016-03-31 Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr)

Country Status (7)

Country Link
US (1) US11576932B2 (en)
EP (1) EP3436572A4 (en)
JP (1) JP2019509753A (en)
KR (2) KR20190006952A (en)
CN (2) CN109477073B (en)
SG (1) SG11201708680PA (en)
WO (1) WO2017171631A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018056897A1 (en) 2016-09-23 2018-03-29 Lion Tcr Pte. Ltd. An hbv antigen specific binding molecules and fragments thereof
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
JP2021527427A (en) 2018-06-21 2021-10-14 ビー−モーゲン・バイオテクノロジーズ，インコーポレーテッド Transposon-mediated gene transfer and related compositions, systems, and methods of the enhanced hAT family
IL280682B (en) 2018-08-13 2022-08-01 Rootpath Genomics Inc High-throughput cloning of bifirate immunoreceptor conjugated polynucleotides and their applications
CN113939527A (en) * 2019-01-11 2022-01-14 新加坡科技研究局 Use of HLA-A*11:01-restricted hepatitis B virus (HBV) peptides to identify HBV-specific CD8+ T cells
MX2021012207A (en) 2019-04-05 2021-12-10 Rootpath Genomics Inc Compositions and methods for t-cell receptor gene assembly.
WO2021148110A1 (en) 2020-01-21 2021-07-29 Lion Tcr Pte. Ltd. Hbv specific tcr library and its use as personalised medicine
US20230174934A1 (en) * 2020-04-27 2023-06-08 Vanderbilt University Lymphocytes lacking perforin function
KR20230066419A (en) * 2020-09-11 2023-05-15 내셔널 유니버시티 오브 싱가포르 Immunosuppressant drug-resistant armed TCR T cells for immuno-therapy of organ transplant patients

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322211A1 (en) * 2001-07-12 2003-01-29 Canvac Methods and compisitions for activation human t cells in vitro
GB0509318D0 (en) * 2005-05-06 2005-06-15 Chiron Srl TCR-independent activation of T cells
JP2008539758A (en) * 2005-05-11 2008-11-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Method for rapid expansion of antigen-specific T-cells
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
EP1795599A1 (en) * 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
CN101361969B (en) * 2008-01-29 2011-05-11 广州市恺泰生物科技有限公司 Therapeutic hepatitis b vaccine and preparation method and use thereof
DK2288700T3 (en) * 2008-05-09 2017-05-22 Agency Science Tech & Res HBV EPITOP-REACTIVE EXOGEN T-CELL RECEPTOR (TCR) AND APPLICATIONS THEREOF
ES2657846T3 (en) * 2010-04-29 2018-03-07 Epiontis Gmbh Detection of immune cells, in particular T lymphocytes by DNA methylation analysis of CCR6 genes
CA2849045C (en) * 2011-09-29 2020-11-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lentiviral vectors pseudotyped with mutant baev glycoproteins
MX380109B (en) * 2012-08-20 2025-03-12 Fred Hutchinson Cancer Center Star METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY.
JP2015529685A (en) * 2012-09-17 2015-10-08 ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Compositions and methods for the treatment of amyotrophic lateral sclerosis
CN102964326B (en) * 2012-11-06 2015-11-18 北京大学 There is compound of MEK inhibit feature and preparation method thereof and application
CN109096274B (en) * 2013-12-11 2022-07-01 比奥根Ma公司 Biaryl compounds useful in the treatment of human oncological, neurological and immunological diseases
EP3083674B1 (en) * 2013-12-19 2018-10-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Influenza-specific t-cell receptor and its uses in the detection, prevention and/or treatment of influenza
EP3189148A4 (en) * 2014-09-02 2018-05-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
HK1243333A1 (en) * 2014-10-31 2018-07-13 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
EP3445391B1 (en) * 2016-04-13 2025-07-02 Vivia Biotech, S.L. Ex vivo bite-activated t cells
WO2018056897A1 (en) * 2016-09-23 2018-03-29 Lion Tcr Pte. Ltd. An hbv antigen specific binding molecules and fragments thereof
SG10201705285SA (en) * 2017-06-27 2019-01-30 Agency Science Tech & Res Antisense oligonucleotides
US11903968B2 (en) * 2017-07-21 2024-02-20 Cellectis Engineered immune cells resistant to tumor microenvironment
EP3927835A1 (en) * 2019-02-19 2021-12-29 European Molecular Biology Laboratory Cell penetrating transposase
CN111607565A (en) * 2020-06-04 2020-09-01 河南大学 An in vitro expansion method of Beiping monkey T cells

Also Published As

Publication number Publication date
EP3436572A4 (en) 2019-11-20
JP2019509753A (en) 2019-04-11
KR20240091293A (en) 2024-06-21
EP3436572A1 (en) 2019-02-06
CN109477073A (en) 2019-03-15
CN118147079A (en) 2024-06-07
WO2017171631A1 (en) 2017-10-05
US20190192566A1 (en) 2019-06-27
US11576932B2 (en) 2023-02-14
KR20190006952A (en) 2019-01-21
CN109477073B (en) 2024-04-12

Similar Documents

Publication Publication Date Title
SG11201708680PA (en) Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr)
IL280073B (en) Genetically modified cells containing a modified human t cell receptor alpha constant region gene
IL261910B (en) Electrolyte for rechargeable electrochemical cell
SG10201912516SA (en) Multiplexed single cell gene expression analysis using template switch and tagmentation
GB2539612B (en) Positive electrode active material for lithium secondary cell
HUE045660T2 (en) Cell id management for discovery reference signals for small cells in lte
IL254565A0 (en) Generating virus or other antigen-specific t cells from a naive t cell population
EP3108224B8 (en) Reference electrode insert for an electrochemical test cell
EP3276721A4 (en) Electrochemical reaction unit and fuel cell stack
HUE049347T2 (en) Method for generating pluripotent stem cells containing an antigen-specific T cell receptor gene
PL3529267T3 (en) T cell receptor
PL3688826T3 (en) Battery pack including cell restraint
EP3206246A4 (en) Electrolyte film for fuel cell
ZA201805017B (en) Safe anode for electrochemical cells
ZA201802528B (en) Electrode-supported tubular solid-oxide electrochemical cell
GB201710655D0 (en) Electrochemical cell
GB201714180D0 (en) Transduced cell cryoformulation
PL3195397T3 (en) An electrolyte membrane for use in an electrochemical cell
EP3151320A4 (en) Redox catalyst, electrode material, electrode, membrane electrode assembly for fuel cells, and fuel cell
PL3446352T3 (en) Electrochemical cell including electrode isolation frame
ZA201804586B (en) Fuel cell electrolyte management device
HUE065059T2 (en) Battery pack including cell restraint
HK40005376B (en) Non-activated t cells expressing exogenous virus- specific t cell receptor (tcr)
HK40003034A (en) Non-activated t cells expressing exogenous virus-specific t cell receptor (tcr)
IL252248A0 (en) Electrode for electrochemical cells and composition thereof